secwatch.observer — SEC 8-K summary
======================================

Issuer:     ORAMED PHARMACEUTICALS INC. (ORMP)
CIK:        0001176309
Form:       8-K
Filed at:   2023-09-13T23:59:59+00:00
Accession:  0001213900-23-076238
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oramed restructures Scilex acquisition; enters non-binding term sheets for Securities Transfer by Sept 19
--------------------------------------------------------------------------------

- Scilex declared winning bidder for its own securities from Sorrento; aggregate consideration ~$110M plus ~$12.25M legal fee assumption.
- Two paths: Hudson Bay funds $115M (Option 1) or Scilex assumes Oramed's Senior DIP Loan and Oramed gets secured Note (Option 2).
- If Option 2, Oramed receives 13M warrants at $0.01/sh and 4M warrants at $11.50/sh in Scilex stock; board observer right.
- Closing expected Sept 19, 2023; Bankruptcy Court approved term sheets on Sept 12.
- Upon closing, Oramed and Sorrento terminate Stock Purchase Agreement and release all claims.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1176309/000121390023076238/0001213900-23-076238-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1176309/000121390023076238/ea185123-8k_oramed.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-076238

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer